Eruptive basal cell carcinoma and lenalidomide: rising awareness among dermatologists

Because of its higher level of safety compared to its parent medicine, thalidomide, lenalidomide (L) is chosen for the treatment of multiple myeloma. We report a patient who, within a month of using L, developed more than 10 basal cell carcinomas.

Detalles Bibliográficos
Autores principales: Pagliarello, Calogero, Girardelli, Carlo Renè, Stanganelli, Ignazio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PAGEPress Publications, Pavia, Italy 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10099294/
https://www.ncbi.nlm.nih.gov/pubmed/37063400
http://dx.doi.org/10.4081/dr.2022.9534
Descripción
Sumario:Because of its higher level of safety compared to its parent medicine, thalidomide, lenalidomide (L) is chosen for the treatment of multiple myeloma. We report a patient who, within a month of using L, developed more than 10 basal cell carcinomas.

Ejemplares similares